EMA Authorised: Vyndaqel (tafamidis) — Pfizer Europe MA EEIG

View source ↗

Summary

European Medicines Agency authorises Vyndaqel (tafamidis) for Amyloidosis via Pfizer Europe MA EEIG.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyloidosis

Drugs mentioned

• Vyndaqel (tafamidis)

Snippet

Status: Authorised. Therapeutic area: Amyloidosis. MAH: Pfizer Europe MA EEIG. Decision date: 12/03/2026. Orphan medicine